SEC Form 4 · accession 0001209191-19-003261
Intra-Cellular Therapies, Inc. · ITCI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew Satlin
Officer — EVP and Chief Medical Officer
Period of report
Jan 8, 2019
Accepted (ET)
Jan 10, 2019 · 4:28 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567514
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $12.73 | Jan 8, 2019 | A | 94,443 | A | — | Jan 7, 2029 | Common Stock | 94,443 | 94,443 | D |
| Restricted Stock UnitsF2,F3 | — | Jan 8, 2019 | A | 68,735 | A | — | — | Common Stock | 68,735 | 68,735 | D |
Explanation of responses
- F1On January 8, 2019, the reporting person was granted options to purchase 94,443 shares of common stock, vesting in three equal annual installments beginning on the first anniversary of the grant date.
- F2Each restricted stock unit represents a contingent right to receive one share of common stock.
- F3On January 8, 2019, the reporting person was granted 68,735 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.